LRMR net incomeQ2 2026-$32.78M
LRMR net income was -$32.78M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$26.18M a year earlier. For the full fiscal 2025 it was -$165.67M, compared with -$80.60M in fiscal 2024.
Larimar Therapeutics Inc. (LRMR) financials
For the twelve months ended Jun 30, 2026, Larimar Therapeutics Inc. reported -$172.60M of net income.
- Net income, TTM
- -$172.60M
- Cash
- $92.69M
- Market cap
- $279.4M
FY2016FY2019
FY2016FY2025
FY2016FY2025
LRMR revenue and earnings growth
LRMR EPSQ3 2025-$0.61
LRMR diluted EPS was -$0.61 in fiscal Q3 2025 (ended Sep 30, 2025), compared with -$0.24 a year earlier. For the full fiscal 2024 it was -$1.32, compared with -$0.84 in fiscal 2023.
LRMR free cash flowFY2025-$113.29M
LRMR free cash flow was -$113.29M for fiscal 2025 (ended Dec 31, 2025), compared with -$71.28M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $0 | $0 | $0 | $0 |
| Research and development | $154.22M | $73.28M | $27.67M | $24.25M | $38.40M | $31.41M | $20.79M | $47.93M | $40.84M | $39.94M |
| Selling, general and admin | $18.27M | $17.61M | $14.09M | $12.28M | $12.07M | $11.40M | $2.42M | $13.19M | $12.16M | $18.29M |
| Operating income | -$172.50M | -$90.89M | -$41.76M | -$36.53M | -$50.47M | -$42.80M | -$23.21M | -$61.12M | -$53.00M | -$58.23M |
| Interest expense | - | - | - | - | - | - | $1.77M | $1.90M | $165.0K | $529.0K |
| Pre-tax income | -$165.67M | -$80.60M | -$36.95M | -$35.35M | -$50.64M | -$42.48M | -$23.18M | -$61.37M | -$52.03M | -$57.88M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$165.67M | -$80.60M | -$36.95M | -$35.35M | -$50.64M | -$42.48M | -$23.13M | -$61.37M | -$52.03M | -$57.88M |
| EPS, basic | - | -$1.32 | -$0.84 | -$1.37 | -$2.95 | -$3.57 | -$3.80 | -$1.90 | -$1.90 | -$2.12 |
| EPS, diluted | - | -$1.32 | -$0.84 | -$1.37 | -$2.95 | -$3.57 | -$3.80 | -$1.90 | -$1.90 | -$2.12 |
| Diluted shares | - | 61.3M | 43.9M | 25.8M | 17.2M | 11.9M | 6.1M | 32.2M | 27.4M | 27.3M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $85.41M | $33.22M | $26.75M | $26.82M | $70.10M | $68.15M | $1.01M | $49.33M | $40.78M | $32.35M |
| Current assets | $142.02M | $195.30M | $90.17M | $120.74M | $72.20M | $97.95M | $4.75M | $121.33M | $104.92M | $130.90M |
| Total assets | $145.84M | $200.22M | $95.94M | $126.41M | $78.67M | $104.69M | $5.20M | $121.76M | $105.51M | $131.62M |
| Current liabilities | $64.80M | $24.36M | $9.51M | $10.71M | $8.85M | $8.99M | $5.89M | $13.31M | $7.29M | $9.89M |
| Total debt | - | - | - | - | - | - | $14.54M | $20.00M | $20.00M | $3.18M |
| Total liabilities | $67.76M | $28.41M | $14.21M | $15.50M | $14.25M | $14.99M | $5.89M | $28.49M | $27.29M | $9.89M |
| Shareholders' equity | $78.08M | $171.81M | $81.72M | $110.90M | $64.41M | $89.69M | -$694.0K | $2.91M | $78.22M | $121.73M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$113.20M | -$70.76M | -$33.46M | -$27.57M | -$42.10M | -$42.20M | -$22.70M | -$51.49M | -$43.78M | -$51.98M |
| Capital expenditures | $91.0K | $515.0K | $164.0K | $100.0K | $333.0K | $62.0K | $83.0K | $108.0K | $55.0K | $660.0K |
| Free cash flow | -$113.29M | -$71.28M | -$33.62M | -$27.67M | -$42.44M | -$42.26M | -$22.78M | -$51.59M | -$43.84M | -$52.63M |
| Investing cash flow | $100.31M | -$85.39M | $33.35M | -$90.96M | $24.17M | $17.09M | -$83.0K | -$6.87M | $35.65M | $51.45M |
| Financing cash flow | $65.09M | $161.88M | $30.0K | $75.26M | $19.89M | $93.59M | $19.39M | $66.91M | $16.56M | -$2.71M |
| Stock-based compensation | $7.00M | $8.80M | $7.62M | $6.62M | $5.47M | $2.16M | $129.0K | $9.63M | $8.30M | $10.11M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -212.2% | -46.9% | -45.2% | -31.9% | -78.6% | -47.4% | - | -2106.0% | -66.5% | -47.5% |
| Return on assets | -113.6% | -40.3% | -38.5% | -28.0% | -64.4% | -40.6% | -444.8% | -50.4% | -49.3% | -44.0% |
| Current ratio | 2.19 | 8.02 | 9.49 | 11.28 | 8.16 | 10.89 | 0.81 | 9.12 | 14.39 | 13.23 |
| Debt to equity | - | - | - | - | - | - | - | 6.86 | 0.26 | 0.03 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $28.00M | $25.03M | $59.37M | $44.93M | $23.37M | $26.55M | $26.74M | $13.92M | $19.68M | $12.94M | $10.65M | $6.58M |
| Selling, general and admin | $6.35M | $6.09M | $4.64M | $4.57M | $4.42M | $4.64M | $4.55M | $4.34M | $4.92M | $3.79M | $3.51M | $3.75M |
| Operating income | -$34.35M | -$31.12M | -$64.02M | -$49.50M | -$27.79M | -$31.19M | -$31.29M | -$18.26M | -$24.60M | -$16.73M | -$14.16M | -$10.34M |
| Income tax | - | - | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - | - |
| Net income | -$32.78M | -$29.61M | -$62.50M | -$47.71M | -$26.18M | -$29.28M | -$28.82M | -$15.50M | -$21.63M | -$14.65M | -$12.99M | -$9.06M |
| EPS, basic | - | - | - | -$0.61 | -$0.41 | -$0.46 | -$0.47 | -$0.24 | -$0.34 | -$0.27 | -$0.29 | -$0.21 |
| EPS, diluted | - | - | - | -$0.61 | -$0.41 | -$0.46 | -$0.47 | -$0.24 | -$0.34 | -$0.27 | -$0.29 | -$0.21 |
| Diluted shares | - | - | - | 78.3M | 64.0M | 64.0M | - | 63.8M | 63.8M | 53.6M | - | 43.9M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $92.69M | $177.91M | $85.41M | $90.14M | $20.59M | $21.13M | $33.22M | $35.07M | $32.31M | $110.13M | $26.75M | $38.72M |
| Current assets | $160.67M | $204.98M | $142.02M | $183.22M | $145.56M | $165.49M | $195.30M | $213.26M | $231.13M | $230.95M | $90.17M | $98.48M |
| Total assets | $165.30M | $208.51M | $145.84M | $187.35M | $149.99M | $170.18M | $200.22M | $219.02M | $237.16M | $248.21M | $95.94M | $103.95M |
| Current liabilities | $34.17M | $47.76M | $64.80M | $45.12M | $26.65M | $22.13M | $24.36M | $16.29M | $21.16M | $12.84M | $9.51M | $6.56M |
| Total liabilities | $37.92M | $50.48M | $67.76M | $48.31M | $30.13M | $25.90M | $28.41M | $20.62M | $25.76M | $17.36M | $14.21M | $11.24M |
| Shareholders' equity | $127.38M | $158.03M | $78.08M | $139.04M | $119.85M | $144.27M | $171.81M | $198.40M | $211.40M | $230.84M | $81.72M | $92.71M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$44.03M | -$44.61M | - | - | -$19.38M | -$26.54M | -$21.82M | -$24.55M | -$13.99M | -$10.41M | -$9.34M | -$9.20M |
| Capital expenditures | - | - | $0 | $23.0K | $19.0K | $49.0K | $179.0K | $62.0K | - | - | - | - |
| Free cash flow | - | - | - | - | -$19.40M | -$26.59M | -$21.99M | -$24.61M | - | - | - | - |
| Investing cash flow | -$40.91M | $29.00M | - | - | $18.84M | $14.45M | $19.20M | $27.27M | -$63.49M | -$68.36M | -$2.63M | -$46.43M |
| Financing cash flow | -$435.0K | $108.11M | - | - | - | - | $36.0K | $30.0K | -$334.0K | $162.15M | $0 | - |
| Stock-based compensation | $2.15M | $1.98M | $1.56M | $1.78M | $1.83M | $1.83M | $2.41M | $1.96M | $2.30M | $2.13M | $1.92M | $1.82M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 4.70 | 4.29 | 2.19 | 4.06 | 5.46 | 7.48 | 8.02 | 13.10 | 10.93 | 17.99 | 9.49 | 15.02 |
Source: XBRL data Larimar Therapeutics Inc. files with the SEC, latest filing dated Aug 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
LRMR peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| LRMR | - | - | -$172.60M | - | $279.4M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
LRMR FAQ
4 questionsIs LRMR profitable?
No. Larimar Therapeutics Inc. reported a net loss of $172.60M for the twelve months ended Jun 30, 2026.How much cash and debt does LRMR have?
Larimar Therapeutics Inc. reported $92.69M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did LRMR last report financial results?
The latest statements here come from Larimar Therapeutics Inc.'s 10-Q filed on Aug 4, 2026, covering the period ended Jun 30, 2026.Where does this LRMR financial data come from?
Quantisnow builds these statements from the structured XBRL data Larimar Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.